Skip to main content
Top
Published in: Clinical Rheumatology 3/2004

01-06-2004 | Original Article

Increased serum levels of interleukin-8 in polyarteritis nodosa and Behçet’s disease

Authors: Alzírton de Lira Freire, Manoel Barros Bertolo, Antônio José de Pinho Jr, Adil Muhib Samara, Sandra Regina Muchinechi Fernandes

Published in: Clinical Rheumatology | Issue 3/2004

Login to get access

Abstract

The pathogenesis of Behçet’s disease (BD) and polyarteritis nodosa (PAN) is not yet well established. Endothelial cells have been shown to express chemokines that are involved in inflammatory processes. Interleukin-8 (IL-8) is a potent chemoattractant and activator of neutrophils. We evaluated serum IL-8 levels in patients with PAN and BD. We measured serum IL-8 levels in 21 patients with BD and 16 with PAN. Sera from 30 age-matched healthy blood donors were used as normal controls. Serum IL-8 levels were measured by an enzyme-linked immunosorbent assay (ELISA). The mean serum IL-8 level of the active BD (1522.31 pg/ml) and that of the active PAN (654.8 pg/ml) was significantly higher than that of the normal controls (40.39 pg/ml, P <0.05). There was no difference in mean serum IL-8 levels between patients with inactive disease and normal controls. We found higher serum levels of IL-8 in those patients with more severe disease. These results suggest that IL-8 may play a role in the pathogenesis of PAN and/or BD. Our study also suggests a possible relation between serum IL-8 levels and the severity of these diseases.
Literature
1.
go back to reference International Study Group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080PubMed International Study Group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080PubMed
2.
go back to reference Lightfoot RW Jr, Michel BA, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33:1088–1093PubMed Lightfoot RW Jr, Michel BA, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33:1088–1093PubMed
3.
go back to reference al-Dalaan A, al-Sedairy S, al-Balaa S et al. (1995) Enhanced interleukin 8 secretion in circulation of patients with Behçet’s disease. J Rheumatol 22:904–907PubMed al-Dalaan A, al-Sedairy S, al-Balaa S et al. (1995) Enhanced interleukin 8 secretion in circulation of patients with Behçet’s disease. J Rheumatol 22:904–907PubMed
4.
go back to reference Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS (1999) Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease. J Interferon Cytokine Res 19:91–104CrossRefPubMed Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS (1999) Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease. J Interferon Cytokine Res 19:91–104CrossRefPubMed
5.
go back to reference Sneller MC, Fauci AS (1997) Pathogenesis of vasculitis syndromes. Med Clin North Am 81:221–242PubMed Sneller MC, Fauci AS (1997) Pathogenesis of vasculitis syndromes. Med Clin North Am 81:221–242PubMed
6.
go back to reference Sundy JS, Haynes BF (1995) Pathogenic mechanisms of vessel damage in vasculitis syndromes. Rheum Dis Clin North Am 21:861–881 Sundy JS, Haynes BF (1995) Pathogenic mechanisms of vessel damage in vasculitis syndromes. Rheum Dis Clin North Am 21:861–881
7.
go back to reference Fresko I, Soy M, Hamuryudan V et al. (1998) Genetic anticipation in Behçet’s disease. Ann Rheum Dis 57:45–48PubMed Fresko I, Soy M, Hamuryudan V et al. (1998) Genetic anticipation in Behçet’s disease. Ann Rheum Dis 57:45–48PubMed
8.
go back to reference Luqmani RA, Bacon PA, Moots RJ et al. (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJ Med 87:671–678 Luqmani RA, Bacon PA, Moots RJ et al. (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJ Med 87:671–678
9.
go back to reference Mege JL, Dilsen N, Sanguedolce V et al. (1993) Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxid generation in Behçet’s disease. A comparative study with familial mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549PubMed Mege JL, Dilsen N, Sanguedolce V et al. (1993) Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxid generation in Behçet’s disease. A comparative study with familial mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549PubMed
10.
go back to reference Itoh R, Takenaka T, Okitsu-Negishi S, Matsushima K, Mizoguchi M (1994) Interleukin 8 in Behçet’s Disease. J Dermatol 21:397–404PubMed Itoh R, Takenaka T, Okitsu-Negishi S, Matsushima K, Mizoguchi M (1994) Interleukin 8 in Behçet’s Disease. J Dermatol 21:397–404PubMed
11.
go back to reference Sahin S, Akoglu T, Direskeneli H, Sem LS, Lawrence R (1996) Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet’s disease. Ann Rheum Dis 55:128–133PubMed Sahin S, Akoglu T, Direskeneli H, Sem LS, Lawrence R (1996) Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet’s disease. Ann Rheum Dis 55:128–133PubMed
12.
go back to reference Wang LM, Kitteringham N, Mineshita S et al. (1997) The demonstration of serum interleukin-8 and superoxide dismutase in Adamantiades–Behçet’s disease. Arch Dermatol Res 289:444–447CrossRefPubMed Wang LM, Kitteringham N, Mineshita S et al. (1997) The demonstration of serum interleukin-8 and superoxide dismutase in Adamantiades–Behçet’s disease. Arch Dermatol Res 289:444–447CrossRefPubMed
13.
go back to reference Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC (2000) Adamantiades–Behçet’s disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 201:37–39CrossRefPubMed Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC (2000) Adamantiades–Behçet’s disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 201:37–39CrossRefPubMed
14.
go back to reference Evereklioglu C, Er H, Turkoz Y, Cekmen M (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with behçet’s disease. Mediators Inflamm 11:87–93CrossRefPubMed Evereklioglu C, Er H, Turkoz Y, Cekmen M (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with behçet’s disease. Mediators Inflamm 11:87–93CrossRefPubMed
15.
go back to reference Zouboulis CC, Katsantonis J, Ketteler R et al. (2000) Adamantiades–Behcet’s disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 292:279–284CrossRefPubMed Zouboulis CC, Katsantonis J, Ketteler R et al. (2000) Adamantiades–Behcet’s disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 292:279–284CrossRefPubMed
16.
go back to reference Jennette JC (2002) Implications for pathogenesis of patterns of injury in small and medium-sized-vessel vasculitis. Cleveland Clin J Med 69 (suppl 2):SII 33–38 Jennette JC (2002) Implications for pathogenesis of patterns of injury in small and medium-sized-vessel vasculitis. Cleveland Clin J Med 69 (suppl 2):SII 33–38
17.
go back to reference Mayet WJ, Schwarting A, Barreiros AP, Schlaak J, Neurath M (1999) Anti-PR-3 antibodies induce endothelial IL-8 release. Eur J Clin Invest 29:973–979CrossRefPubMed Mayet WJ, Schwarting A, Barreiros AP, Schlaak J, Neurath M (1999) Anti-PR-3 antibodies induce endothelial IL-8 release. Eur J Clin Invest 29:973–979CrossRefPubMed
Metadata
Title
Increased serum levels of interleukin-8 in polyarteritis nodosa and Behçet’s disease
Authors
Alzírton de Lira Freire
Manoel Barros Bertolo
Antônio José de Pinho Jr
Adil Muhib Samara
Sandra Regina Muchinechi Fernandes
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-003-0851-x

Other articles of this Issue 3/2004

Clinical Rheumatology 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.